Opposing roles for cannabinoid receptor type-1 (CB 1) and transient receptor potential vanilloid Type-1 channel (TRPV1) on the modulation of panic-like responses in rats

Neuropsychopharmacology

Volumn 37, Issue 2, 2012, Pages 478-486

  Casarotto, Plínio C ^a   Terzian, Ana Luisa B ^b,c   Aguiar, Daniele C ^d   Zangrossi, Hélio ^a   Guimares, Francisco S ^a   Wotjak, Carsten T ^b   Moreira, Fabrício A ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

anandamide; anxiety; cannabinoid; panic; periaqueductal gray; vanilloid

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ANANDAMIDE; ARACHIDONYL 2 CHLORO ETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CAPSAZEPINE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTROSTIMULATION; HISTOLOGY; IMMUNOFLUORESCENCE; MALE; NERVE CELL; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

ANILIDES; ANIMALS; ARACHIDONIC ACIDS; CAPSAICIN; CINNAMATES; DRUG INTERACTIONS; ELECTRIC STIMULATION; MALE; MICROINJECTIONS; PANIC; PERIAQUEDUCTAL GRAY; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TRPV CATION CHANNELS;

EID: 84856060775     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.207     Document Type: Review

References (64)

1. Aguiar DC, Terzian AL, Guimarães FS, Moreira FA (2009). Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 205: 217-225.
2. Bandler R, Keay KA, Floyd N, Price J (2000). Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. Brain Res Bull 53: 95-104.
3. Beckett S, Marsden CA (1995). Computer analysis and quantification of periaqueductal grey-induced defense behaviour. J Neurosci Methods 58: 157-161.
4. Casarotto PC, de Bortoli VC, Corrêa FM, Resstel LB, Zangrossi Jr H (2010). Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA. Int J Neuropsychopharmacol 13: 573-582.
5. Cassano T, Gaetani S, Macheda T, Laconca L, Romano A, Morgese MG et al (2010). Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolasedeficient mice. Psychopharmacology (Berl), print copy in press (originally published online 2 November 2010 at http://www.springerlink.com/content/r6351r2q7t881t25/fulltext.pdf).
6. Cavanaugh DJ, Chesler AT, Jackson AC, Sigal YM, Yamanaka H, Grant R et al (2011). Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J Neurosci 31: 5067-5077.
7. Chavez AE, Chiu CQ, Castillo P (2010). TRPV1 activation by endogenous anandamide triggers post synaptic long-term depression in dentate gyrus. Nat Neurosci 13: 1511-1519.
8. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 1405-1415.
9. Del-Ben CM, Graeff FG (2009). Panic disorder: is the PAG involved? Neural Plast 2009: 108135.
10. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455. (Pubitemid 351649182)
11. Di Marzo V (2010). Anandamide server two masters in the brain. Nat Neurosci 13: 1446-1448.
12. Di Marzo V, Bisogno T, De Petrocellis L (2001). Anandamide: some like it hot. Trends Pharmacol Sci 22: 346-349. (Pubitemid 32592472)
13. Dielenberg RA, Hunt GE, McGregor IS (2001). 'When a rat smells a cat': the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience 104: 1085-1097. (Pubitemid 32701968)
14. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA et al (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45: 594-604. (Pubitemid 36980816)
15. Gawa NR, Tamir R, Klionsky L, Norman MH, Louis JC, Wild KD et al (2005). Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol Pharmacol 68: 1524-1533. (Pubitemid 41654336)
16. Grueter BA, Brasnjo G, Malenka RC (2010). Post synaptic TRPV1 triggers cell-type specific long-term depression in the nucleus accumbens. Nat Neurosci 13: 1519-1526.
17. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM et al (2004). Identification and characterization of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46: 133-149. (Pubitemid 37494747)
18. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395-1398. (Pubitemid 35340861)
19. Haller J, Varga B, Ledent C, Freund TF (2004). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15: 299-304. (Pubitemid 39062560)
20. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
21. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
22. Hogg S, Michan L, Jessa M (2006). Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. Neuropharmacology 51: 141-145.
23. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F et al (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400-8405. (Pubitemid 34651064)
24. Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT (2009). Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 8: 685-698.
25. Jenck F, Moreau JL, Martin JR (1995). Dorsal periaqueductal grayinduced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57: 181-191.
26. Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V et al (2006). Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26: 6677-6686. (Pubitemid 44315229)
27. Kasckow JW, Mulchahey JJ, Geracioti Jr TD (2004). Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 28: 291-295. (Pubitemid 38130135)
28. Katon WJ (2006). Clinical practice. Panic disorder. N Engl J Med 354: 2360-2367.
29. Kawahara H, Drew GM, Christie MJ, Vaughan CW (2010). Inhibition of fatty acid amide hydrolase unmasks CB(1) receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br J Pharmacol, print copy in press (originally published online 22 December 2010 at http://onlinelibrary.wiley.com/doi/10.1111/j. 1476-5381.2010.01157.x/pdf).
30. Krieger JE, Graeff FG (1985). Defensive behavior and hypertension induced by glutamate in the midbrain central gray of the rat. Braz J Med Biol Res 18: 61-67. (Pubitemid 15225623)
31. Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS (2008). Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593: 73-78.
32. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316: 969-982. (Pubitemid 43345268)
33. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F et al (2007). Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27: 832-939.
34. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534. (Pubitemid 34851398)
35. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159: 379-387. (Pubitemid 34143362)
36. McGaraughty S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P et al (2003). Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 90: 2702-2710. (Pubitemid 37266534)
37. McNaughton N, Gray JA (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 61: 161-176. (Pubitemid 32119264)
38. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R et al (2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97: 3655-3660. (Pubitemid 30183358)
39. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F et al (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34: 593-606.
40. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B et al (2007). When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 317: 1079-1083. (Pubitemid 47330191)
41. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB et al (2009). Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 2009: 625469.
42. Moreira FA, Aguiar DC, Guimarães FS (2007). Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52: 958-965. (Pubitemid 46227483)
43. Nashold Jr BS, Wilson WP, Slaughter DG (1969). Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30: 14-24.
44. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. 3rd edn. Academic Press: San Diego.
45. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884. (Pubitemid 37351427)
46. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM (2004). Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 141: 1118-1130. (Pubitemid 38582249)
47. Roy-Byrne PP, Craske MG, Stein MB (2006). Panic disorder. Lancet 368: 1023-1032. (Pubitemid 44353694)
48. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E et al (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18: 1292-1301. (Pubitemid 351769783)
49. Santos CJ, Stern CA, Bertoglio LJ (2008). Attenuation of anxietyrelated behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 19: 357-360.
50. Schenberg LC, Bittencourt AS, Sudré EC, Vargas LC (2001). Modeling panic attacks. Neurosci Biobehav Rev 25: 647-659. (Pubitemid 34136894)
51. Schütz MT, de Aguiar JC, Graeff FG (1985). Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. Psychopharmacology (Berl) 85: 340-345. (Pubitemid 15123111)
52. Silveira PE, Silveira NA, Morini Vde C, Kushmerick C, Naves LA (2010). Opposing effects of cannabinoids and vanilloids on evoked quantal release at the frog neuromuscular junction. Neurosci Lett 473: 97-101.
53. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227-230. (Pubitemid 30072640)
54. Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F et al (2007b). Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 27: 13739-13749. (Pubitemid 350278253)
55. Starowicz K, Nigam S, Di Marzo V (2007a). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114: 13-33. (Pubitemid 46498161)
56. Terzian AL, Aguiar DC, Guimarães FS, Moreira FA (2009). Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 19: 188-195.
57. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M et al (2001). Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21: 1104-1109. (Pubitemid 32128755)
58. Tóth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z et al (2005). Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135: 162-168. (Pubitemid 40602409)
59. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411. (Pubitemid 28062631)
60. Vaughan CW, Connor M, Bagley EE, Christie MJ (2000). Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57: 288-295. (Pubitemid 30084505)
61. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-11203.
62. Xing J, Li J (2007). TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 97: 503-511. (Pubitemid 46143373)
63. Zygmunt PM, Julius D, Di Marzo V, Hogestatt ED (2000). AnandamideFthe other side of the coin. Trends Pharmacol Sci 21: 43-44.
64. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457. (Pubitemid 29361798)